1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Stem Cells Transplantation in Oncology -Pipeline Insights, 2015

Summary
DelveInsight’s, “Stem Cells Transplantation in Oncology -Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mode of therapy. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Stem Cells Oncology.
- The Report gives insights on 20+ products with 15+ companies, which are active in this field.
- In depth analysis of pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages.
- Comparative study of drugs under development.
- Therapeutics assessment by monotherapy and combination products and molecule type drug information, drug origin and mode of therapy.
- R&D activities and technologies used along with the pipeline therapies in development.
- Information related to collaborations in Stem Cells Transplantation Industry.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mode of therapy.

Scope
- A snapshot of the global Stem Cell Transplantation therapy market scenario.
- Coverage of stem cell transplantation therapies under development across the globe
- Competitive landscape of investigational products in Stem Cells Therapy
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, licensors & collaborators, development partner and technology information

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Stem Cell therapy
- Devise corrective measures for pipeline projects by understanding therapy area specific to Stem Cell Transplantation therapies
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
- Identifying the upcoming leaders in the Stem Cell Transplantation for oncology market in the coming years.
- Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table Of Contents

Stem Cells Transplantation in Oncology -Pipeline Insights, 2015
- Stem Cell Overview
- Types of stem cell transplants for treating cancer
- Allogeneic and Autologous Transplant
- Future of Stem Cells Transplantation in Oncology
- Current Market Senario
- Stem Cell Transplantation Analysis
- Stem Cells Therapy - Origin
- Stem Cells Therapy - Mode of Therapy
- Stem Cells Therapy - Technology
- Stem Cell Transplantation in Oncology Overview
- Pipeline Therapeutics
- An Overview of Pipeline Products for Stem Cell Oncology
- Therapeutics under Development by Companies
- Last Stage Products (Phase III and Filed)
- Comparative Analysis
- Drug 1
- Product Description:
- Research and Development
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug 2
- Product Description
- Research and Development
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Drug 3
- Product Description
- Research and Development
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Drug 4
- Product Description
- Research and Development
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Source of Stem Cells
- Assessment by Mode of Therapy
- Assessment by Drug Origin
- Discontinued Products
- Dormant Products
- Methodology
- Consulting Services
- About DelveInsight
- Contact Us
- Disclaimer

List of Tables
Table 1: Companies with Stem cells Technology, 2015
Table 2: Stem Cell Therapies Developed using Technology, 2015
Table 3: Total Number of Stem Cells, 2015
Table 4: Number of Products under Development for Stem Cell Oncology, 2015
Table 5: Number of Products under Development by Companies, 2015
Table 6: Last Stage Products (Phase III and Filed), 2015
Table 7: Mid Stage Products (Phase II), 2015
Table 8: Early Stage Products (Phase I and IND), 2015
Table 9: Discovery and Pre-clinical Stage Products, 2015
Table 10: Assessment by Monotherapy Products, 2015
Table 11: Assessment by Route of Administration, 2015
Table 12: Assessment by Stage and Route of Administration, 2015
Table 13: Assessment by Source of stem Cell, 2015
Table 14: Assessment by Mode of Therapy, 2015
Table 15: Assessment by Stage and Mode of Therapy, 2015
Table 16: Assessment by Drug Origin, 2015
Table 17: Assessment by Stage and Drug Origin, 2015
Table 18: Discontinued Products, 2015
Table 19: Dormant Products, 2015

List of Figures
Figure 1: Number of Stem Cell Therapies by Origin, 2015
Figure 2: Number of Stem Cell Therapies by Mode of Therapy, 2015
Figure 3: Stem Cell Technology Analysis by Companies and Number of Therapies, 2015
Figure 4: Total Number of Stem Cells, 2015
Figure 5: Number of Products under Development for Stem Cell Oncology, 2015
Figure 6: Last Stage Products (Phase III and Filed), 2015
Figure 7: Mid Stage Products (Phase II), 2015
Figure 8: Early Stage Products (Phase I and IND), 2015
Figure 9: Discovery and Pre-clinical Stage Products, 2015
Figure 10: Assessment by Monotherapy Products, 2015
Figure 11: Assessment by Route of Administration, 2015
Figure 12: Assessment by Stage and Route of Administration, 2015
Figure 13: Assessment by Source of Stem Cells, 2015
Figure 14: Assessment by Mode of Therapy, 2015
Figure 15: Assessment by Stage and Mode of Therapy, 2015
Figure 16: Assessment by Drug Origin, 2015
Figure 17: Assessment by Stage and Drug origin, 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.